☆ 4.8 Article

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy

Thomas Walter Georgi et al.

Summary: Assessing the value of FDG-PET/CT in predicting patient outcomes after CAR-T cell therapy, it was found that PET-1 results were significantly associated with patient prognosis. Patients with CMR had better outcomes, while those without CMR had poorer outcomes.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

Ana Jimenez-Ubieto et al.

Summary: In this study, we screened follicular lymphoma patients for liquid biopsy MRD biomarkers using NGS panel and found trackable mutations in a majority of the samples. We used ultra-deep sequencing to track these mutations in follow-up samples and found that positive LiqBio-MRD correlated with a higher risk of progression during treatment. The combination of LiqBio-MRD and PET/CT provided a sensitive and specific identification of patients who progressed in less than two years. This non-invasive approach should be considered in future clinical trials.

LEUKEMIA (2023)

Add to Collection

Letter Oncology

Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas

Clara Sortais et al.

LEUKEMIA & LYMPHOMA (2023)

Add to Collection

Article Oncology

Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study

Ismael Fernandez-Miranda et al.

Summary: This study examined the significance of circulating tumor DNA (ctDNA) in predicting response to therapy and early disease progression in follicular lymphoma (FL) patients. The results showed that baseline ctDNA levels are associated with early disease progression and treatment response in FL.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study

Sally F. Barrington et al.

Summary: Complete metabolic response (CMR) on PET/CT is an independent predictor of overall survival in first-line treatment of high-tumor-burden follicular lymphoma. Patients who do not achieve CMR have poorer outcomes, with those with a Deauville score of 5 showing shorter progression-free survival and time to next treatment than those with a score of 4.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson et al.

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler et al.

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

Add to Collection

Letter Hematology

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

Andrea Kuhnl et al.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo et al.

Summary: Observational studies and stand-alone trials have shown that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy have poor outcomes. This pooled analysis of clinical trials validates POD24 as a robust indicator of poor FL survival and identifies clinical predictors of early death and progression, which can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.

BLOOD (2022)

Add to Collection

Article Oncology

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde et al.

Summary: The study evaluated the safety and efficacy of fixed-duration mosunetuzumab in patients with relapsed or refractory follicular lymphoma. The results showed that mosunetuzumab has a favorable safety profile and induces high rates of complete remissions.

LANCET ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

Ricardo Sanchez et al.

Summary: In this study, a novel DNA-based next-generation sequencing (NGS) method was developed for the detection and monitoring of BCR::ABL1 kinase domain (KD) mutations in chronic myeloid leukemia (CML) and B-cell precursor acute lymphoblastic leukemia (ALL) Philadelphia (Ph)-positive patients. This method showed high sensitivity and specificity, and was able to detect mutations even in patients with low levels of disease.

SCIENTIFIC REPORTS (2022)

Add to Collection

Meeting Abstract Hematology

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Martin Dreyling et al.

BLOOD (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine

Elena Landete et al.

Summary: This case report highlights a 33-year-old woman with a history of Classic Hodgkin Lymphoma who developed hypermetabolic lymph nodes after receiving the adenovirus-vectored COVID-19 vaccine, which were initially concerning for disease relapse but later resolved, emphasizing the importance of considering false positives in such scenarios.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Article Oncology

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Matthew J. Frank et al.

Summary: This study demonstrated the prognostic value of circulating tumor DNA (ctDNA) in predicting outcomes of large B-cell lymphoma patients undergoing axicabtagene ciloleucel (axi-cel) treatment. Higher baseline ctDNA concentrations were associated with progression post-treatment and development of toxicities. Additionally, patients with undetectable ctDNA 1 week after axi-cel infusion had higher rates of durable response compared to those with detectable ctDNA.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

David M. Kurtz et al.

Summary: PhasED-seq improves the sensitivity of ctDNA detection by using multiple somatic mutations in individual DNA fragments, outperforming previous methods with better limits of detection in the ppm range. In patients with B cell lymphomas, PhasED-seq can detect more cases of ctDNA positivity associated with worse outcomes. The method is also applicable to solid tumors.

NATURE BIOTECHNOLOGY (2021)

Add to Collection

Article Otorhinolaryngology

18FDG-PET/CT Specificity for the Detection of Lymphoma Recurrence in the Tonsils

Jonathan D. West et al.

Summary: This retrospective case series study explored the specificity of PET/CT in identifying lymphoma recurrence in the oropharynx. Most patients who underwent tonsillectomy following abnormal PET/CT imaging findings had benign pathology, leading to a false-positive rate of 93%. The study questions the routine use of tonsillectomy in this patient population.

OTO OPEN (2021)

Add to Collection

Article Oncology

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng et al.

NATURE MEDICINE (2020)

Add to Collection

Article Hematology

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Frederick L. Locke et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

Esther Onecha et al.

HAEMATOLOGICA (2019)

Add to Collection

Article Oncology

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

John P. Leonard et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Hematology

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Valeria Spina et al.

BLOOD (2018)

Add to Collection

Article Oncology

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment

Ana Jimenez-Ubieto et al.

HEMATOLOGICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

David M. Kurtz et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

F. Morschhauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

Marc Sorigue et al.

HEMATOLOGICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

R. Marcus et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

Ana Jimenez-Ubieto et al.

CANCER MEDICINE (2017)

Add to Collection

Article Hematology

Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

Ana Jimenez-Ubieto et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

Add to Collection

Article Oncology

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

C. Y. Cheah et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Hematology

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

Bruce D. Cheson et al.

BLOOD (2016)

Add to Collection

Article Oncology

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

Clementine Sarkozy et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Mark Roschewski et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Hematology

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn et al.

BLOOD (2014)

Add to Collection

Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Cell Biology

Genetics of Follicular Lymphoma Transformation

Laura Pasqualucci et al.

CELL REPORTS (2014)

Add to Collection

Review Medicine, General & Internal

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Stephen M. Ansell et al.

MAYO CLINIC PROCEEDINGS (2012)

Add to Collection

Article Hematology

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

W Hiddemann et al.

BLOOD (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.